STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’
STAT
MARCH 18, 2024
CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.
Let's personalize your content